Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
citalopram + risperidone
- Development stage
- Preclinical
- Lead developer
- Lundbeck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Citalopram + risperidone is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Citalopram is a selective serotonin reuptake inhibitor (SSRI) used primarily for depression, anxiety disorders, and other mood disorders. It works by increasing serotonin levels in the brain by inhibiting its reuptake into neurons[7]. Risperidone is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, and irritability associated with autistic disorder. It acts as an antagonist at dopamine D2 receptors and serotonin 5-HT2A receptors[6]. The combination has been studied for potential augmentation effects in treatment-resistant depression or negative symptoms in schizophrenia[4][5]. However, combining these drugs can increase the risk of serious side effects such as irregular heart rhythm (QT prolongation)[1][2].
- Other names
- citalopram and risperidonerisperidone and citalopram
02
Targets
HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on citalopram + risperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on citalopram + risperidone.